Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Omeros shares rise 34% as promising drug for eye surgeries achieves PhIII endpoint

This article was originally published in Scrip

Executive Summary

Omeros saw its shares gain $2.58 (34%), to $10.22 on 13 March after it claimed that its investigational combination drug for use in eye surgeries, OMS302, achieved it primary endpoint, which was maintaining pupil dilation (mydriasis) in intraocular lens replacement surgeries, in a US Phase III trial. The combination drug also resulted in a reduction of postoperative pain (secondary endpoint).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016619

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel